Zdrowie i gospodarka · 26/06/2026

FDA Clears RECTIV Nitroglycerin Ointment for Sale, Citing Lack of Safety or Effectiveness Concerns

The US Food and Drug Administration (FDA) has made a determination that RECTIV (nitroglycerin) ointment, 0.4%, was not withdrawn from sale due to concerns over its safety or effectiveness, allowing the agency to continue approving abbreviated new drug applications (ANDAs) for the product as long as they meet relevant requirements.